Cigna Corp’s Express Scripts unit reached a settlement with the U.S. Federal Trade Commission on February 4, 2026 that ends a lawsuit alleging the PBM’s insulin‑pricing practices violated antitrust and consumer‑protection laws. The agreement requires Express Scripts to overhaul its pricing model, increase transparency, and lower the price of insulin at the point of sale, but it does not impose a monetary penalty.
Under the settlement, Express Scripts will publish detailed pricing disclosures and adjust its fee structure to align rebates more closely with actual drug costs. The PBM will also implement a phased rollout of the new model over the next several months, with the first stage focused on public reporting of rebate flows and the second stage on recalibrating rebate thresholds to prevent artificial list‑price inflation. The changes are designed to address the FTC’s core allegation that the PBM’s rebate‑driven model encouraged higher list prices for insulin while passing only a fraction of the savings to payers and patients.
The settlement comes amid intensified scrutiny of the “Big Three” PBMs—Express Scripts, CVS Caremark, and UnitedHealth’s Optum Rx—which the FTC began investigating in September 2024. While the FTC paused proceedings against Cigna’s subsidiaries for 14 days in late January to allow settlement talks, it has also been negotiating with CVS and UnitedHealth. The outcome for Express Scripts therefore sets a precedent that could influence the regulatory trajectory for the other PBMs and the broader industry’s pricing practices.
Financially, the settlement could compress Cigna’s pharmacy‑benefit‑services margin. Analysts expect the transition costs and the need to reduce rebate volumes to weigh on the PBM segment’s profitability in the short term. However, the absence of a cash penalty mitigates immediate cash‑flow impact, and the company’s management has indicated that the transparency measures are intended to build payer trust and potentially open new contract opportunities. The settlement’s timing—just one day before Cigna’s fourth‑quarter 2025 earnings release on February 5—means investors will soon assess the real‑world cost of the changes against the company’s guidance.
The broader implication is that the settlement signals a shift toward greater regulatory oversight of PBM rebate practices. By requiring a more transparent pricing model, the FTC is pushing the industry toward a system where list prices more accurately reflect true drug costs. For Cigna, the move may improve its competitive positioning if it can demonstrate a more patient‑friendly pricing structure, but it also introduces a new compliance burden that could affect future earnings and margin targets.
The settlement underscores the growing risk profile of PBMs in a regulatory environment that is also seeing proposed Department of Labor rules on spread pricing and ongoing legislative efforts to reform the PBM model. Cigna’s strategic focus on reducing medical cost growth and expanding specialty pharmacy capabilities will now need to balance these regulatory demands with the imperative to maintain profitability in its PBM segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.